ADA Deficiency clinical trials at UCLA

2 in progress, 1 open to eligible people

Showing trials for

  • Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector

    open to eligible people ages 1 month and up

    The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human ADA gene transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.

    Los Angeles, California

  • LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

    Sorry, accepting new patients by invitation only

    This observational long-term follow-up study is designed to collect safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA LV encoding for human adenosine deaminase (ADA) gene (EFS-ADA LV), as part of the OTL-101 clinical development program. No investigational medicinal product will be administered to these patients as part of the OTL-101-6 study.

    Los Angeles, California and other locations

Our lead scientists for ADA Deficiency research studies include .

Last updated: